HK1210425A1 - Compositions containing hc-ha/ptx3 complexes and methods of use thereof hc-ha/ptx3 - Google Patents
Compositions containing hc-ha/ptx3 complexes and methods of use thereof hc-ha/ptx3Info
- Publication number
- HK1210425A1 HK1210425A1 HK15111254.1A HK15111254A HK1210425A1 HK 1210425 A1 HK1210425 A1 HK 1210425A1 HK 15111254 A HK15111254 A HK 15111254A HK 1210425 A1 HK1210425 A1 HK 1210425A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ptx3
- methods
- compositions containing
- complexes
- ptx3 complexes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670571P | 2012-07-11 | 2012-07-11 | |
PCT/US2013/049983 WO2014011813A1 (en) | 2012-07-11 | 2013-07-10 | Compositions containing hc-ha/ptx3 complexes and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210425A1 true HK1210425A1 (en) | 2016-04-22 |
Family
ID=48916179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111254.1A HK1210425A1 (en) | 2012-07-11 | 2015-11-13 | Compositions containing hc-ha/ptx3 complexes and methods of use thereof hc-ha/ptx3 |
Country Status (9)
Country | Link |
---|---|
US (5) | US10040821B2 (ko) |
EP (2) | EP3838293A1 (ko) |
JP (3) | JP2015528001A (ko) |
KR (1) | KR102236805B1 (ko) |
CN (2) | CN114652816A (ko) |
CA (1) | CA2878163A1 (ko) |
ES (1) | ES2846789T3 (ko) |
HK (1) | HK1210425A1 (ko) |
WO (1) | WO2014011813A1 (ko) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
EP1933852B1 (en) | 2005-09-27 | 2018-12-19 | TissueTech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
KR102236805B1 (ko) | 2012-07-11 | 2021-04-05 | 티슈테크, 인코포레이티드 | Hc-ha/ptx3 복합체를 함유하는 조성물 및 이의 사용 방법 |
EP3160512B1 (en) * | 2014-06-25 | 2019-05-22 | Novartis AG | Compositions and methods for visualization of the vitreous |
US20170204151A1 (en) * | 2014-07-28 | 2017-07-20 | Darwin J. Prockop | Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders |
DE102015210890A1 (de) | 2014-10-02 | 2016-04-07 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Trockenprodukt aus Obst und/oder Gemüse sowie Verfahren zur Herstellung |
EP3297645A4 (en) * | 2015-05-20 | 2018-12-12 | Tissuetech, Inc. | Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
CN104988118A (zh) * | 2015-07-08 | 2015-10-21 | 深圳爱生再生医学科技有限公司 | 脐带间充质干细胞的制备方法 |
CN104988119A (zh) * | 2015-07-08 | 2015-10-21 | 深圳爱生再生医学科技有限公司 | 沃顿胶消化液 |
CN105353113B (zh) * | 2015-11-05 | 2017-09-08 | 中国科学院武汉病毒研究所 | 洛拉曲塞或其药学上可接受的盐在制备治疗或预防疱疹病毒感染药物中的应用 |
EP3426253A4 (en) | 2016-03-11 | 2019-11-06 | Ardea Biosciences, Inc. | CXCR-2 INHIBITORS FOR TREATING CRYSTALLINE ARTHROPATHY RELATED DISORDERS |
JP6967260B2 (ja) * | 2016-03-28 | 2021-11-17 | 学校法人慶應義塾 | 移植片対宿主病の治療剤又は予防剤、ファイブロサイト浸潤抑制剤、及び涙液減少と杯細胞の減少の抑制剤 |
CN106950366B (zh) * | 2017-02-15 | 2019-03-22 | 中国医学科学院北京协和医院 | 一种acpa阴性的ra诊断标志物及其应用 |
US10251917B1 (en) * | 2017-09-19 | 2019-04-09 | Gary M. Petrucci | Methods and materials for treating tumors |
TWI741216B (zh) * | 2017-09-19 | 2021-10-01 | 臻崴生物科技有限公司 | 專一性抑制或減緩ptx3與ptx3受體結合之單株抗體或其抗原結合片段及其用途 |
US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
AU2019223946B2 (en) | 2018-02-22 | 2021-05-20 | Alcon Inc. | Ocular implant and delivery system |
CN110090228A (zh) * | 2018-04-18 | 2019-08-06 | 浙江大学 | 人羊膜上皮细胞在自身免疫性疾病中的治疗用途 |
JP2021532152A (ja) | 2018-07-27 | 2021-11-25 | アペルタ バイオサイエンシズ,エルエルシー | デモデックスにより誘発される眼の異常および顔面の異常を治療するためのスピノシン配合 |
CN113164567A (zh) * | 2018-09-24 | 2021-07-23 | 不列颠哥伦比亚大学 | 在治疗皮肤状况中调节颗粒酶k活性 |
CN110946988B (zh) * | 2018-09-26 | 2022-11-29 | 臻崴生物科技有限公司 | 短肽用于制备抑制或减缓虾过敏反应的药物组合物的用途 |
EP3870147A4 (en) * | 2018-10-24 | 2022-08-31 | Prothera Biologics, Inc. | INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF |
WO2020097251A1 (en) * | 2018-11-07 | 2020-05-14 | Tissuetech, Inc. | Methods of cellular reprogramming |
AU2020260133A1 (en) * | 2019-04-16 | 2021-11-18 | Lifenet Health | Birth tissue-derived products and preparation and uses thereof |
JP2022535089A (ja) * | 2019-06-06 | 2022-08-04 | アロア・バイオサージェリー・リミテッド | 生物活性剤及びそれに関連した方法 |
US20230172994A1 (en) * | 2019-06-20 | 2023-06-08 | Tissuetech, Inc. | Methods of promoting vasculogenesis |
KR102166453B1 (ko) * | 2020-02-03 | 2020-10-15 | 중앙대학교 산학협력단 | Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물 |
EP4103592A4 (en) * | 2020-02-12 | 2024-01-10 | BioTissue Holdings Inc. | METHODS OF DESTRUCTING OR INHIBITING THE GROWTH OF CANCER CELLS |
CN112924679A (zh) * | 2021-01-29 | 2021-06-08 | 沈阳金域医学检验所有限公司 | Ptx-3在医学检测中的新应用 |
KR102678583B1 (ko) * | 2021-05-31 | 2024-06-27 | 중앙대학교 산학협력단 | Hapln1을 포함하는 혈관질환 예방 또는 치료용 조성물 |
KR102641504B1 (ko) * | 2021-12-30 | 2024-03-04 | 주식회사 하플사이언스 | Hapln1을 포함하는 안구건조증의 예방 또는 치료용 조성물 |
WO2023211823A1 (en) * | 2022-04-25 | 2023-11-02 | Biotissue Holdings Inc. | Compositions and methods relating to pooled fetal support tissue |
CN114870031B (zh) * | 2022-05-20 | 2023-07-07 | 四川大学 | 一种cd44靶向的紫杉烷类纳米晶体及其制备方法与应用 |
CN114939190B (zh) * | 2022-06-14 | 2024-01-12 | 健诺维(成都)生物科技有限公司 | 一种用于青光眼治疗的引流管材料及其制备方法 |
CN115843780B (zh) * | 2022-11-18 | 2023-06-20 | 广州瑞泰生物科技有限公司 | 生物膜保存液及其制备方法和应用 |
CN115845141B (zh) * | 2023-03-02 | 2023-05-16 | 健诺维(成都)生物科技有限公司 | 一种干态羊膜的制备方法及应用 |
CN117159588B (zh) * | 2023-11-01 | 2024-02-13 | 北京国卫生物科技有限公司 | 脐带间充质干细胞治疗骨关节炎的细胞治疗方法 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
BE795384A (fr) | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
US4141973A (en) | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
SE8200751L (sv) | 1982-02-09 | 1983-08-10 | Olle Larm | Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US5093487A (en) | 1986-01-06 | 1992-03-03 | Mobay Corporation | Low viscosity high molecular weight filter sterilizable hyaluronic acid |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US5037677A (en) | 1984-08-23 | 1991-08-06 | Gregory Halpern | Method of interlaminar grafting of coatings |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
AU1537292A (en) | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
KR100274734B1 (ko) | 1991-11-22 | 2000-12-15 | 제이코버스 코넬리스 레이서 | 리제드로네이트 지연-방출성 조성물 |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5437287A (en) | 1992-08-17 | 1995-08-01 | Carbomedics, Inc. | Sterilization of tissue implants using iodine |
WO1994008568A1 (en) | 1992-10-16 | 1994-04-28 | Nippon Shinyaku Co., Ltd. | Method of manufacturing wax matrices |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5336518A (en) | 1992-12-11 | 1994-08-09 | Cordis Corporation | Treatment of metallic surfaces using radiofrequency plasma deposition and chemical attachment of bioactive agents |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US6203755B1 (en) | 1994-03-04 | 2001-03-20 | St. Jude Medical, Inc. | Electron beam sterilization of biological tissues |
US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
US5932545A (en) | 1997-03-17 | 1999-08-03 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
US20030068815A1 (en) | 1999-02-11 | 2003-04-10 | Stone Kevin R. | Sterilized xenograft tissue |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6521179B1 (en) | 1999-08-11 | 2003-02-18 | Biomedical Design, Inc. | Sterilization |
US6573249B2 (en) | 2000-02-15 | 2003-06-03 | Alphamed Pharmaceutical Corp. | Topical wound therapeutic compositions |
KR20010098716A (ko) | 2000-04-19 | 2001-11-08 | 김재찬 | 안구표면질환 치료용 양막 추출물 |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
CN100542612C (zh) | 2001-08-14 | 2009-09-23 | 特拉维夫大学未来技术研发有限公司 | 类脂化糖胺聚糖颗粒及其在诊断和治疗用药物和基因传递中的应用 |
US20030180181A1 (en) | 2002-02-01 | 2003-09-25 | Teri Greib | Methods for sterilizing tissue |
TWI290055B (en) | 2002-03-14 | 2007-11-21 | Tissuetech Inc | Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes |
ES2398239T3 (es) | 2003-11-10 | 2013-03-14 | The Scripps Research Institute | Composiciones y procedimientos para inducir la desdiferenciación celular |
US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
GB0514567D0 (en) | 2005-07-15 | 2005-08-24 | Univ Nottingham | Surgical membrane |
EP1933852B1 (en) * | 2005-09-27 | 2018-12-19 | TissueTech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
EA014166B1 (ru) | 2005-12-13 | 2010-10-29 | Киото Юниверсити | Ядерный фактор перепрограммирования |
US20080102135A1 (en) | 2006-10-28 | 2008-05-01 | Franck Jean Ollivier | Use of equine amniotic membrane in ophthalmic surgeries in veterinary medicine |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US8093365B2 (en) | 2008-03-03 | 2012-01-10 | New York University | Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same |
US20100000375A1 (en) | 2008-07-07 | 2010-01-07 | Steinbock Robert C | Tamper resistant jackbolts for a tensioner |
ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
JP2013523823A (ja) | 2010-04-08 | 2013-06-17 | アントフロゲネシス コーポレーション | 胎盤幹細胞を用いるサルコイドーシスの治療 |
TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
WO2012149486A1 (en) | 2011-04-28 | 2012-11-01 | Tissuetech, Inc. | Methods of modulating bone remodeling |
KR102236805B1 (ko) | 2012-07-11 | 2021-04-05 | 티슈테크, 인코포레이티드 | Hc-ha/ptx3 복합체를 함유하는 조성물 및 이의 사용 방법 |
CA2926320A1 (en) | 2013-10-07 | 2015-04-16 | Mor Research Applications Ltd. | Treatments for proliferative vitreoretinopathy |
EP3093339B1 (en) | 2014-01-08 | 2021-02-24 | Samsung Life Public Welfare Foundation | Stem cells derived from pure chorionic trophoblast layer and cell therapy comprising same |
CN107002035A (zh) | 2014-08-14 | 2017-08-01 | 阿威他国际有限公司 | 干细胞组合物和生产用于治疗应用的干细胞的方法 |
EP3297645A4 (en) | 2015-05-20 | 2018-12-12 | Tissuetech, Inc. | Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
WO2017096617A1 (zh) | 2015-12-11 | 2017-06-15 | 郭镭 | 一种用于分步培养hUC-MSC的试剂盒及采用所述试剂盒获得的hUC-MSC |
US20180362923A1 (en) | 2015-12-11 | 2018-12-20 | Lei Guo | Method for separating and extracting huc-msc from wharton's jelly tissue of umbilical cord |
US11098280B2 (en) | 2015-12-11 | 2021-08-24 | Lei Guo | Serum-free culture medium and preparation method and application therefor |
WO2017136557A1 (en) | 2016-02-05 | 2017-08-10 | Petrucci Gary M | Methods and materials for treating nerve injuries and neurological disorders |
US20170354692A1 (en) | 2016-06-13 | 2017-12-14 | MAM Holdings of West Florida, L.L.C. | Amniotic fluid formulation for treatment of lung disorders |
CN109641078A (zh) | 2016-08-24 | 2019-04-16 | 阿瑟雷克斯股份有限公司 | 用于修复损伤的组织 |
AU2017339344B2 (en) | 2016-10-05 | 2023-10-19 | Cellresearch Corporation Pte. Ltd. | A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium |
US20180126036A1 (en) | 2016-11-07 | 2018-05-10 | Ise Professional Testing & Consulting Services, Inc. | Decellularized biomaterial from mammalian tissue |
US20180163177A1 (en) | 2016-12-11 | 2018-06-14 | Healthbanks Biotech Co. Ltd. | Serum-free culture medium and method for expanding hematopoietic stem cells |
US10993904B2 (en) | 2016-12-23 | 2021-05-04 | Inscobee Inc. | Transplantation implant for promoting hair growth |
US20180177989A1 (en) | 2016-12-28 | 2018-06-28 | Regen Medical Inc. | Vaginal rejuvenation methods and devices |
CN108324736A (zh) | 2017-01-18 | 2018-07-27 | 傅毓秀 | 脐带间质干细胞用于治疗肺纤维化的用途 |
US20180264049A1 (en) | 2017-03-20 | 2018-09-20 | Batu Biologics, Inc. | Immunotherapy of Aberrant Ocular Angiogenesis by Placental Vaccination |
US20180271914A1 (en) | 2017-03-21 | 2018-09-27 | Noveome Biotherapeutics, Inc. | Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury |
US20180311408A1 (en) | 2017-05-01 | 2018-11-01 | Trojan Medical Solutions, LLC | Amnion based conduit tissue |
WO2018220489A2 (en) | 2017-06-02 | 2018-12-06 | Janssen Biotech, Inc. | Methods of obtaining cells from human postpartum umbilical cord arterial tissue |
US20180344777A1 (en) | 2017-06-02 | 2018-12-06 | Janssen Biotech, Inc. | Method of modulating müller glia cells |
WO2019087130A2 (en) | 2017-11-03 | 2019-05-09 | Janssen Biotech, Inc. | Method of inhibiting angiogenesis |
GB2582521B (en) | 2017-11-14 | 2022-07-13 | Cook Biotech Inc | Preserved tissue products and related methods |
-
2013
- 2013-07-10 KR KR1020157003180A patent/KR102236805B1/ko active IP Right Grant
- 2013-07-10 ES ES13745221T patent/ES2846789T3/es active Active
- 2013-07-10 WO PCT/US2013/049983 patent/WO2014011813A1/en active Application Filing
- 2013-07-10 CA CA2878163A patent/CA2878163A1/en active Pending
- 2013-07-10 CN CN202210284199.XA patent/CN114652816A/zh active Pending
- 2013-07-10 CN CN201380047367.2A patent/CN104619352B/zh active Active
- 2013-07-10 EP EP20208234.3A patent/EP3838293A1/en active Pending
- 2013-07-10 US US14/414,047 patent/US10040821B2/en active Active
- 2013-07-10 EP EP13745221.5A patent/EP2872181B1/en active Active
- 2013-07-10 JP JP2015521783A patent/JP2015528001A/ja active Pending
-
2015
- 2015-11-13 HK HK15111254.1A patent/HK1210425A1/xx unknown
-
2016
- 2016-07-20 US US15/214,706 patent/US10253065B2/en active Active
- 2016-07-27 JP JP2016147710A patent/JP6472142B2/ja active Active
-
2019
- 2019-02-12 US US16/274,123 patent/US10717763B2/en active Active
- 2019-05-31 JP JP2019103107A patent/JP2019178144A/ja active Pending
-
2020
- 2020-06-10 US US16/898,309 patent/US11518782B2/en active Active
-
2022
- 2022-11-01 US US18/051,796 patent/US20230279048A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11518782B2 (en) | 2022-12-06 |
CN104619352A (zh) | 2015-05-13 |
US10040821B2 (en) | 2018-08-07 |
JP2017014234A (ja) | 2017-01-19 |
US20200308219A1 (en) | 2020-10-01 |
CN104619352B (zh) | 2022-02-18 |
CN114652816A (zh) | 2022-06-24 |
EP2872181A1 (en) | 2015-05-20 |
JP2019178144A (ja) | 2019-10-17 |
JP2015528001A (ja) | 2015-09-24 |
JP6472142B2 (ja) | 2019-02-20 |
US20150166624A1 (en) | 2015-06-18 |
US20230279048A1 (en) | 2023-09-07 |
WO2014011813A1 (en) | 2014-01-16 |
US20190169231A1 (en) | 2019-06-06 |
EP3838293A1 (en) | 2021-06-23 |
US20160376305A1 (en) | 2016-12-29 |
US10253065B2 (en) | 2019-04-09 |
ES2846789T3 (es) | 2021-07-29 |
KR102236805B1 (ko) | 2021-04-05 |
CA2878163A1 (en) | 2014-01-16 |
EP2872181B1 (en) | 2020-11-18 |
US10717763B2 (en) | 2020-07-21 |
KR20150053753A (ko) | 2015-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210425A1 (en) | Compositions containing hc-ha/ptx3 complexes and methods of use thereof hc-ha/ptx3 | |
HK1212729A1 (zh) | 核糖核酸調節子組合物和使用方法 | |
IL235436A0 (en) | Anti-pcsk9 preparations and their use | |
ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
EP2929874A4 (en) | COSMETIC ADDITIVE AND COSMETIC PRODUCT CONTAINING SAME | |
EP2836218A4 (en) | PROBIOTIC COMPOSITIONS AND METHODS OF USE | |
EP2834322A4 (en) | BIOCHARBON COMPOSITIONS AND METHODS OF USE | |
EP2836212A4 (en) | NOVEL COMPOSITIONS AND METHOD | |
EP2881450A4 (en) | LATENT ADDITIVE AND COMPOSITION CONTAINING SAME | |
EP2964235A4 (en) | ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE | |
HK1212251A1 (en) | Topical compositions and methods of use | |
HK1208375A1 (en) | Improved complexes and compositions containing curcumin | |
HK1209031A1 (en) | Polysaccharide compositions and methods of use | |
GB201315350D0 (en) | Methods and compositions | |
EP2906041A4 (en) | COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND | |
GB201315347D0 (en) | Methods and compositions | |
EP2874641A4 (en) | COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF | |
EP2852370A4 (en) | FLASH-CONTAINING COMPOSITIONS AND METHODS OF USE | |
EP2922871A4 (en) | METHODS AND COMPOSITIONS FOR FACTOR IX PROTEINS | |
EP2895186A4 (en) | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | |
IL233961B (en) | The composition of a phytogenic supplement and methods of its use | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
EP2834635A4 (en) | COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR | |
HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
EP2924046A4 (en) | NEW COMPLEX AND USE |